Manjari Pandey, MD
Hematology & Oncology · Danville, PANPI 1932339876
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,371 of the $3,562 with a category attached, or 66.6%. 41 manufacturers reported payments, led by Merck at 36.9% of the total. Reporting peaked in 2019 at $2,150 and has fallen 53.5% since, to $1,000 in 2025.
Across 122 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Incyte Corporation$275
- Johnson & Johnson$266
- AstraZeneca$209
- Genentech USA, Inc.$170
- Novocure Inc.$137
- plus $1K from 35 others
Across 33 payments — averaging $5490.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$171K
- Novocure GmbH$10K
What the payments were for
- Travel & lodging$90525%
- Food & beverage$2,37167%
- Education$2858%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $1,315 |
| Incyte Corporation | 10 | $275 |
| Johnson & Johnson(2 entities) | 14 | $266 |
| AstraZeneca | 9 | $209 |
| Genentech USA, Inc. | 6 | $170 |
| Novocure Inc. | 4 | $137 |
| Amgen | 8 | $133 |
| Sanofi | 3 | $81 |
| Puma Biotechnology, Inc. | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Lilly USA, LLC | 5 | $68 |
| Seagen Inc. | 3 | $56 |
| AbbVie | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Galvanize Therapeutics, Inc | 1 | $40 |
| Sobi, Inc | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $35 |
| Bayer | 2 | $34 |
| Bristol Myers Squibb | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Novartis | 2 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Genmab U.S., Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Secura Bio, Inc. | 1 | $15 |
| Coherus Oncology, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$979
How this compares
$3,562 in reported general payments places this provider in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 29 | $490,170 |
| IbrancePalbociclib | 29 | $461,404 |
| TagrissoOsimertinib Mesylate | 22 | $379,208 |
| ZejulaNiraparib Tosylate | 13 | $352,694 |
| LonsurfTrifluridine/Tipiracil Hcl | 15 | $166,619 |
| Abiraterone Acetate | 22 | $57,300 |
| EliquisApixaban | 20 | $13,901 |
| Enoxaparin Sodium | 17 | $3,471 |
| Anastrozole | 81 | $2,365 |
| Dexamethasone | 54 | $807 |
| Olanzapine | 54 | $651 |
| Prochlorperazine Maleate | 35 | $437 |
| Omeprazole | 25 | $342 |
| Ondansetron Hcl | 28 | $286 |
| Levothyroxine Sodium | 15 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $14 | $475,30449 claims |
| AstraZenecaTagrisso | $209 | $379,20822 claims |
| Lilly USA, LLCOlanzapine | $68 | $65154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Danville
- Joseph LynchDanville$55K
- Parth RaoDanville$44K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.